<DOC>
	<DOCNO>NCT00506948</DOCNO>
	<brief_summary>The goal clinical research study learn combination rabbit anti-thymocyte globulin ( Thymoglobulin® ) , sirolimus ( Rapamune® ) , mycophenolate mofetil ( Cellcept® ) help prevent graft versus host disease ( GVHD ) . The safety drug combination also study . Primary Objective : To determine efficacy toxicity regimen thymoglobulin , sirolimus mycophenolate mofetil prevention acute GVHD allogeneic stem cell transplantation human leukocyte antigen ( HLA ) identical relate unrelated donor . Secondary Objective : To assess engraftment , chronic GVHD , relapse survival .</brief_summary>
	<brief_title>Thymoglobulin , Sirolimus Mycophenolate Mofetil Prevention Acute Graft-Versus-Host Disease ( GVHD )</brief_title>
	<detailed_description>Rabbit anti-thymocyte globulin ( rATG ) , sirolimus , mycophenolate mofetil ( MMF ) design prevent GVHD . If find eligible take part study , receive rATG needle vein 3-4 hour 4 day stem cell transplant . Beginning 2 day transplant , take sirolimus mouth per day . You continue receive sirolimus 90 day transplant . Beginning Day 60 , start take increasingly low dos study drug . This do taper slowly , drug Day 90 . Beginning day transplant , take MMF mouth 2 time day . You continue take MMF 27 day transplant . Every week ( first 90-100 day transplant ) study visit . At visit , physical exam . Blood ( 1-2 tablespoon ) draw routine test . You remain study 90 day transplantation . You take study intolerable side effect occur . Starting Day 90 transplant , continue follow transplant doctor least every 3 month 1 year transplant . During visit physical exam . Blood ( 1-2 tablespoon ) draw routine test . Your doctor may request additional testing . This investigational study . RATG , sirolimus , MMF FDA approve use transplantation solid organ ( like kidney liver ) . All 3 drug commercially available . This particular combination dose schedule consider investigational . Up 30 patient take part study . All enrol M.D . Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients high risk hematological malignancy , include induction failure treat untreated relapse . High risk hematological malignancy include : Acute myelogenous lymphocytic leukemia induction failure relapse , myelodysplastic syndrome intermediate high risk accord Greenberg criterion , chronic myelogenous leukemia accelerate phase blast crisis , nonHodgkin 's Hodgkin 's lymphoma induction failure relapse chemotherapy refractory relapse chronic lymphocytic leukemia . 2 . HLAidentical sibling match unrelated donor transplant eligible protocol high priority . 3 . Age 1875 year . 4 . Bilirubin &lt; /=1.5 mg/dl , serum glutamicpyruvic transaminase ( SGPT ) &lt; /= 200 IU/ml . 5 . Creatinine &lt; /=1.6 mg/dl . 1 . Regimens include rituximab alemtuzumab preparative regimen . 2 . Patients receive prior treatment gemtuzumab . 3 . Planned condition chemotherapy transplant include gemtuzumab . 4 . Planned condition chemotherapy transplant include busulfan cyclophosphamide regimen . 5 . HIV seropositivity 6 . Uncontrolled infection , respond adequate antimicrobial therapy 7 day treatment . The protocol PI final arbiter eligibility . 7 . Pregnancy 8 . Inability sign consent . 9 . Patients past recipient allogeneic autologous stem cell transplant source .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Graft Versus Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>Allogeneic Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>AHSCT</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>T-Cells</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>rATG</keyword>
	<keyword>Rabbit Antithymocyte Globulin</keyword>
	<keyword>Rapamune</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>Cellcept</keyword>
	<keyword>MMF</keyword>
</DOC>